Form 4: Theodore R. Samuels II Reports Changes in Beneficial Ownership of Bristol-Myers Squibb Co. Stock

Director Theodore R. Samuels II reports acquisition of deferred share units in Bristol-Myers Squibb Co.

Summary

• Theodore R. Samuels II, a director of Bristol-Myers Squibb Co., filed a Form 4 on July 2, 2024, reporting changes in beneficial ownership.
• On June 30, 2024, Samuels acquired 1,203.949 deferred share units, each convertible into one share of common stock upon settlement.
• The price of the deferred share units was $41.53.
• Following the transaction, Samuels beneficially owns 49,712.392 derivative securities.
• These include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a routine transaction by a company director. The acquisition of deferred share units can be seen as a positive sign of alignment with the company's future, but it's not a major event.

Positives

• The acquisition of deferred share units indicates a continued investment and alignment of interests between the director and the company's future performance.

Future Outlook

The deferred share units will be converted into common stock upon settlement, which will occur when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding the director's investment in the company.

Key Dates